Resource Summary Report

Generated by RRID on Aug 28, 2026

OCI-Ly7

RRID:CVCL_1881
Type: Cell Line

Proper Citation

RRID:CVCL_1881

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1881

Proper Citation: RRID:CVCL_1881

Description: Cell line OCI-Ly7 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: PMID:3567358, PMID:8574164, PMID:11807979, PMID:15126345, PMID:19278952, PMID:19358282, PMID:20054396, PMID:20628145, PMID:23257783, PMID:23292937, PMID:23699601, PMID:25485619, PMID:25960936, PMID:27397505, PMID:27566572, PMID:28196595, PMID:30894373, PMID:31160637, PMID:35839778

Comments: Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572)., Population: Caucasian., From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly7

Synonyms: OCI-LY7, OCI-LY-7, OCI-Ly-7, Oci-Ly-7, OCI-Ly 7, OCI-Ly07, OCILY7, Ly7, LY7

Cross References: BTO:BTO_0006414, EFO:EFO_0006711, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:1398, BioSample:SAMN03473439,

cancercelllines:CVCL_1881, Cell_Model_Passport:SIDM00459, ChEMBL-Cells:CHEMBL4523533, ChEMBL-Targets:CHEMBL4523564, Cosmic:1329092, Cosmic:1517649, Cosmic:1541903, Cosmic:1629934, Cosmic:1945199, Cosmic:2276331, Cosmic-CLP:1659819, DepMap:ACH-001617, DSMZ:ACC-688, DSMZCellDive:ACC-688, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS006VZG, ENCODE:ENCBS040MJM, ENCODE:ENCBS062JSC, ENCODE:ENCBS121JKZ, ENCODE:ENCBS141AMI, ENCODE:ENCBS182NFY, ENCODE:ENCBS304FAI, ENCODE:ENCBS581USS, ENCODE:ENCBS699NWP, ENCODE:ENCBS865AAA, ENCODE:ENCBS866AAA, ENCODE:ENCBS886BJZ, GDSC:1659819, GEO:GSM380135, GEO:GSM552453, GEO:GSM562825, GEO:GSM1035333, GEO:GSM1059809, GEO:GSM1374789, PharmacoDB:OCILY7_1187_2019, PRIDE:PXD030304, Progenetix:CVCL_1881, PubChem_Cell_line:CVCL_1881, Wikidata:Q54931777

ID: CVCL_1881

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260815T235419+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly7.

No alerts have been found for OCI-Ly7.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. Blood neoplasia, 3(2), 100214.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer cell, 43(1), 49.

Li J, et al. (2024) Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nature communications, 15(1),

2879.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Martins F, et al. (2024) A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation. Cancer research, 84(6), 808.

Li J, et al. (2023) Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas. bioRxiv : the preprint server for biology.

Schwarzer A, et al. (2023) Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1. Molecular cancer therapeutics, 22(11), 1290.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Preston SEJ, et al. (2022) Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. Molecular cancer therapeutics, 21(4), 511.

Donati G, et al. (2022) Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. Molecular oncology, 16(5), 1132.

Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. Science advances, 8(39), eabq0117.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular cell, 81(10), 2094.

Roberto MP, et al. (2021) Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. Immunity, 54(8), 1807.

Zhang J, et al. (2020) Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. Cell chemical biology, 27(12), 1500.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell reports, 31(13), 107840.

Chu CS, et al. (2020) Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. Molecular cell, 80(5), 845.

Feng H, et al. (2020) Transferrin Receptor Is a Specific Ferroptosis Marker. Cell reports, 30(10), 3411.